AKT1 and prostate cancer: Pretreatment of cells with LY294002 (50 μM, 3 h) followed by saposin C treatment substantially reduced phosphorylation levels of both serine and threonine residues of Akt in AI- and AD-prostate cancer cells (Fig. 2A).